What were the biggest biopharma stories of 2019?
The biggest stories and trends of 2019 - mega-mergers, regulatory controversies, the national conversation about drug pricing and more - will likely have implications for 2020 as well.
BMS, bluebird myeloma CAR-T on way to approval, but others closing in at ASH
In data from several clinical trials released Friday and during the weekend, cell and other therapies for multiple myeloma targeting the antigen BCMA showed strong response rates.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Geopolitical, economic concerns unlikely to stem pharma, life science industry capital deployment, report finds
Deal value for the third quarter fell sharply from what it was in the first and second quarter, but that was due to the absence of the large acquisitions that took place earlier this year rather than an overall downward trend.
Senators urge greater FTC scrutiny over large biopharma mergers
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership
Celgene will have opt-in rights to take responsibility for development, manufacturing and commercialization of T-cell receptor therapies that Immatics develops using its in-house technology.
Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal
Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.
The Role of Consultants in Tackling Healthcare Expenses
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
FDA approves first drug for blood disorder myelofibrosis since 2011
The agency said Friday that it had approved Celgene's Inrebic (fedratinib), the first new drug approved for the disease - a type of rare blood cancer - since the approval of Incyte's Jakafi.
Celgene filing plans potentially mean two more CAR-Ts on the market by end of next year
Celgene plans to file for approval of bb2121 (idecabtagene vicleucel) in myeloma in the first half of 2020, and lisocabtagene maraleucel in lymphoma in the fourth quarter of this year.
BMS to sell $1.6B psoriasis drug to satisfy FTC concerns about Celgene acquisition
The drugmaker said Monday it would sell off the drug Otezla to address concerns about competition that the Federal Trade Commission had expressed in connection to the pending $74 billion deal. According to an analyst, BMS saw Otezla as competitive against its investigational TYK2 inhibitor.
BeiGene regains global rights to checkpoint inhibitor from Celgene
Celgene had been expected to hand the PD-1 checkpoint inhibitor tislelizumab back over to the Chinese company due to its $74 billion acquisition by Bristol-Myers Squibb, which already has its own well-established PD-1 inhibitor, Opdivo.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Merck’s Keytruda fails in Phase III triple-negative breast cancer study, but has a few more chances
The KEYNOTE-119 study failed to show a survival benefit in TNBC patients. The news comes two months after the FDA gave accelerated approval to a rival, Roche's Tecentriq.
CMS delays national coverage determination for CAR-T therapies
In a statement, the agency said that a decision on whether to have Medicare cover the cell therapies would not be issued Friday, but would be forthcoming.
CMS proposes continuing new technology add-on payments for CAR-T cell therapies next year
The agency also proposed increasing the maximum new technology add-on payment from 50 percent to 65 percent for fiscal year 2020.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
Bristol-Myers Squibb, Celgene shareholders vote to approve $74B acquisition deal
BMS's acquisition of Celgene had attracted opposition from two institutional investors. However, one of them withdrew its effort to derail the deal despite continuing to voice opposition.